Vasonatrin Peptide VNP

Research use only, not for human use.

Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.

Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.(In Vitro):Vasonatrin peptide binds with both natriuretic peptide receptor A and B, but with a preference for B. VNP-stimulated cGMP is 11-fold greater in NPRB than NPRA.(In Vivo):The high-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats are subjected to ischemia-reperfusion operation. VNP treatment (100 g/kg iv, 10 min before reperfusion) significantly improved the instantaneous first derivation of left ventricle pressure (LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Treatment hypoxia-induced pulmonary hypertension (HPH) with Vasonatrin peptide for 1 week significantly reduceS mean pulmonary arterial pressure, pulmonary vascular resistance, RVH and muscularization of the pulmonary arteries. Acute intravenous administration of 50 microg/kg Vasonatrin peptide significantly ameliorates pulmonary haemodynamics in HPH rats.

Others

Other Targets

triuretic peptide receptors

——

——

141676-35-9

2865.4

C123H198N36O36S3

>98% (HPLC)

——

——

(-20℃)

With Ice Pack

≥ 2 years